Shatterproof was born with a vision, a vision that our society would prevent and treat addiction as a disease with programs based on science. Without any shame or stigma or judgment – just like any other disease.
Gary Mendell Founder and CEO, Shatterproof
Matthew Might, PhD Professor and Director, Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham Bertrand, my son, outlived every prediction ever made by over a decade, passing away recently just shy of 13 years old – a life six times longer than predicted, and a life far richer than I ever could have hoped for him. Bertrand’s life came to define and propel the field of precision medicine, a movement that continues to transform the lives of people just like him.
The COVID-19 pandemic has highlighted the health disparities and difficulties in being able to reach underrepresented and underserved communities. That’s why CIRM has integrated into its funding and research programs a way to address both diversity and equity.
Maria Millan, MD President and CEO, California Institute for Regenerative Medicine
There is a link between inflammation and blood clotting. One of the horrible consequences of the COVID-19 infection is that people develop blood clots, not only in the legs but in the brain, in the heart muscle, the kidneys and elsewhere. So, this interaction between inflammation and blood clotting is extremely important when looking at the long-term effects of COVID-19 and should be further examined.
Robert S. Rosenson, MD Director of Metabolism and Lipids, Professor of Medicine and Cardiology, Icahn School of Medicine at Mount Sinai
To make cell and gene therapy safe, effective and affordable you must optimize the supply chain. Our industry is just getting off the ground, and it’s forecast to grow at 30 to 40% per year for the next decade. Cryoport is setting the standards for handling cellular and gene therapies from the point of extraction of blood from the patient all the way through the process, to the inoculation on the other end, when the therapy comes back to the patient, whether it’s autologous or allogeneic.
Jerrell W. Shelton Chairman, President and CEO, Cryoport
There is an incredible enthusiasm for longevity, finding cures for the pathologies of aging. I would predict you are going to see major initiatives funding the research, the application of the therapies and the companies themselves. Regenerative medicine is a very important component of this and will be the focus.
Bernard Siegel, JD Executive Director, Regenerative Medicine Foundation
19
Made with FlippingBook flipbook maker